Comparative Pharmacology
Head-to-head clinical analysis: WINSTROL versus XTRENBO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: WINSTROL versus XTRENBO.
WINSTROL vs XTRENBO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Winstrol (stanozolol) is an anabolic steroid derived from dihydrotestosterone. It binds to androgen receptors, increasing protein synthesis and inhibiting catabolic glucocorticoid activity, leading to enhanced muscle growth and reduced inflammation.
XTRENBO (testosterone undecanoate) is an androgen receptor agonist. Testosterone binds to androgen receptors, activating gene transcription that leads to the development and maintenance of male secondary sexual characteristics. It also exerts anabolic effects.
Adults: 2 mg orally three times daily, or 50 mg/mL intramuscularly once monthly (3-4 week intervals) for anabolic effect. Dose range: 1-3 mg/kg/day for hereditary angioedema.
0.25 mg intramuscularly once daily
None Documented
None Documented
Terminal elimination half-life: 9-10 hours for oral administration (stanozolol); parenteral (IM) half-life extends to ~24 hours due to slow release from injection site. Clinical context: supports once-daily oral dosing or weekly IM dosing.
12-18 hours (terminal), requiring twice-daily dosing for sustained serum concentrations.
Primarily renal: 90% as metabolites (glucuronide and sulfate conjugates) and 10% as unchanged drug; minor biliary/fecal elimination (<5%).
Primarily renal (70%) as unchanged drug; 20% biliary/fecal; 10% metabolized to inactive glucuronides.
Category C
Category C
Anabolic Steroid
Anabolic Steroid